id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2769087,90808ceb-73b6-4ab4-8cc8-bbf5a9805b19,1T,O'NEILL AND ASSOCIATES,73134,ANALOGIC,2022,first_quarter,MED,medical technology,"HOUSE OF REPRESENTATIVES,SENATE",5500,,0,1,2022-02-07T08:52:37.947000-05:00
2769373,75a5dcf9-bbed-44b6-a6a0-dd4596c8a13a,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,CURE ALZHEIMER'S FUND,2022,first_quarter,MED,Issues and legislation related to Alzheimer's disease research,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",20000,,0,0,2022-04-01T08:52:55-04:00
2769374,d17c312b-bbc8-446d-93b0-80836f2aad90,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,"PATH DECISION SUPPORT SOFTWARE, LLC",2022,first_quarter,MED,Issues and legislation related to diabetes treatment and diagnosis,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Natl Science Foundation (NSF),SENATE,Veterans Affairs, Dept of (VA)",,,0,0,2022-04-01T08:54:58-04:00
2769586,ad808937-b025-4e19-acb6-3bea610b31ba,Q1,MARSHALL BRACHMAN,6848,BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM,2022,first_quarter,MED,support funding for medical research programs,"HOUSE OF REPRESENTATIVES,SENATE",33000,,0,0,2022-04-03T14:43:25-04:00
2769609,260cdd44-3582-4946-9382-f2c8321cb11a,Q1,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2022,first_quarter,MED,"FY2022 Consolidated Appropriations Act, Division A funding for USDA ARS human nutrition research centers","HOUSE OF REPRESENTATIVES,SENATE",5000,,0,0,2022-04-03T21:03:54-04:00
2769610,220a0d91-861a-4c0e-a734-404e4662860d,1A,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2022,first_quarter,MED,"FY2022 Consolidated Appropriations Act, Division A funding for USDA ARS human nutrition research centers","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-03T21:12:43-04:00
2769718,bbf60b9e-4de3-44a7-81f2-6d24bba19911,Q1,"MAGILL ASSOCIATES, LLC",401103511,THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES,2022,first_quarter,MED,"H.R. 2471 - Consolidated Appropriations Act, 2022 FY 2022 appropriations for the development of a synthetic vaccine","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-04T11:30:35-04:00
2769846,7fe58b10-f35c-499a-83fb-6cd4c6644efa,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2022,first_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2022-04-04T17:45:12-04:00
2769936,a11f5afe-a893-4f7b-a196-1783d39fcac7,Q1,"AUBURN HEALTH STRATEGIES, LLC",292697,AMERICAN PROFICIENCY INSTITUTE,2022,first_quarter,MED,Proficiency testing for clinical laboratories,"Health & Human Services, Dept of (HHS)",,,0,0,2022-04-05T11:23:25-04:00
2769937,f77c3a10-3843-443d-925c-b1f3fcfa9877,Q1,"AUBURN HEALTH STRATEGIES, LLC",292697,AMERICAN PROFICIENCY INSTITUTE,2022,first_quarter,MED,Proficiency testing for clinical laboratories,"Health & Human Services, Dept of (HHS)",,,0,0,2022-04-05T11:23:36-04:00
2769974,9b17da81-b39a-4ef7-8ae6-23a961f4245d,Q1,"MUSCULAR DYSTROPHY ASSOCIATION, INC.",400348610,"MUSCULAR DYSTROPHY ASSOCIATION, INC.",2022,first_quarter,MED,"Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention. Advocated for greater appropriations for the National Center for Advancing Translational Sciences (NCATS) Advocated for greater appropriations for the National Institutes of Health. Advocated for appropriations for HHS, NIH, and FDA to implement the ACT for ALS. Provided feedback and comments to the Senate's PREVENT Act.","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,100000,0,0,2022-04-05T14:19:01-04:00
2770152,3fbe6b76-fdd1-412a-8fe7-35eca3640643,Q1,COVINGTON & BURLING LLP,11195,"SL 2T, LLC (""SMARTLABS"")",2022,first_quarter,MED,"Education and support for policies and funding to advance turnkey, co-located, on-demand pharma grade research laboratory environments, including relating to the PREVENT Pandemics Act (S. 3799) and the ARPA-H Act (H.R. 5585).","HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2022-04-06T13:47:17-04:00
2770204,ba8c9559-6fcd-45b0-97df-dd8672079173,Q1,AMERICAN GASTROENTEROLOGICAL ASSOCIATION,59650,AMERICAN GASTROENTEROLOGICAL ASSOCIATION,2022,first_quarter,MED,"Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program. Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.","HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2022-04-06T15:57:05-04:00
2770262,78e4f507-001e-4a04-a139-7dbc4899863f,Q1,THE HARRIS FIRM,68376,HOLISTIC INDUSTRIES INC.,2022,first_quarter,MED,Issues pertaining to cannabis CSA scheduling.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-04-06T19:10:35-04:00
2770477,66264752-4b68-429b-9cc6-8a3ab9643d6e,Q1,MARSHFIELD CLINIC HEALTH SYSTEM,57830,MARSHFIELD CLINIC HEALTH SYSTEM,2022,first_quarter,MED,"COVID-19, agricultural occupational health, NIOSH","HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2022-04-07T23:30:10-04:00
2770649,c623570e-ef8f-4ef2-9d1e-479d8fc19102,Q1,PROTON THERAPY CONSORTIUM FKA NATIONAL ASSOCIATION FOR PROTON THERAPY,401106232,PROTON THERAPY CONSORTIUM FKA NATIONAL ASSOCIATION FOR PROTON THERAPY,2022,first_quarter,MED,Commercial insurance coverage for radiation oncology; Physician fee schedule; HOPPS 2022; RO APM Model; Medicare & Medicaid coverage for radiation oncology; proton therapy,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-08T11:04:14-04:00
2770710,1887485a-ee75-42e8-87c1-2d54252dc26e,Q1,MCDERMOTT+ LLC,401103287,COALITION FOR 21ST CENTURY MEDICINE,2022,first_quarter,MED,Issues concerning regulation of laboratory-developed tests.,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2022-04-08T12:42:47-04:00
2770980,e89c9a1f-94c5-4a70-b6f7-d9fee978efd8,Q1,"THE PETRIZZO GROUP, INC.",305932,ALLEN INSTITUTE,2022,first_quarter,MED,"Advancing initiatives to fund research of the immune system in underserved and understudied population communities to detect and prevent a downward spiral of vulnerable patients in this pandemic and future pandemics. Advocating for funding of research to develop a specialized suite of ethnically diverse and tissue-specific cell lines with accessible, stable, and reproducible human cell lines that are representative of our diverse population.","HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2022-04-09T16:41:56-04:00
2770984,99a7affa-aa4a-4732-bc5c-9bcd7a8053ea,Q1,"THE PETRIZZO GROUP, INC.",305932,"IBIO, INC.",2022,first_quarter,MED,Advance iBio as the leader in plant-made pharmaceutical manufacturing and collaboration between the U.S. Government for research and development of domestic advanced vaccine manufacturing platforms. COVID-19 pandemic preparedness.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-09T16:47:54-04:00
2770986,648e7da4-f02d-4479-b162-227b22a75f8d,Q1,"THE PETRIZZO GROUP, INC.",305932,"IMMUNITYBIO, INC.",2022,first_quarter,MED,"Federal support for next generation COVID-19 vaccine technology research, development and manufacturing, approval and distribution.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",60000,,0,0,2022-04-09T16:52:57-04:00
2771115,5e0b702a-eb36-4afe-9010-01b34ec91193,Q1,"THE PETRIZZO GROUP, INC.",305932,ACCESS TO ADVANCED HEALTH INSTITUTE,2022,first_quarter,MED,"Advocating for funding for COVID-19 vaccine and therapy development and manufacturing; funding for flu vaccine, support adjuvant inclusion in COVID-19 countermeasures.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2022-04-10T12:06:10-04:00
2771122,c77910c4-9f82-49a8-b1b6-36e46cfa6a60,Q1,"THE PETRIZZO GROUP, INC.",305932,SEATTLE CHILDREN'S HOSPITAL RESEARCH AND FOUNDATION,2022,first_quarter,MED,Pediatricians Accelerate Childhood Therapies Act of 2021 Increased NIH funding for pediatric research,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2022-04-10T12:12:39-04:00
2771130,b483e22a-0a69-4784-930a-4284468eb0e1,Q1,"THE PETRIZZO GROUP, INC.",305932,OMEROS CORPORATION,2022,first_quarter,MED,Advocated for Medicare Part B packaged payment reforms; and the expansion of the non-opioid pain management drug exclusion to the drugs functioning as supplies during a surgical procedure packaging policy. NO PAIN Act,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2022-04-10T12:17:48-04:00
2771202,e978ff25-24f9-48fa-a143-ffb4edad5471,Q1,THE CONSILIO GROUP,400374717,DETECTACHEM,2022,first_quarter,MED,Chemical detection test for COVID-19,"Air Force, Dept of,Defense, Dept of (DOD),Education, Dept of,Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE,White House Office",16500,,0,0,2022-04-11T09:30:33-04:00
2771403,60725d83-6bfd-4491-91ce-62d423573cba,Q1,UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,89235,UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,2022,first_quarter,MED,Issues related to pandemic preparedness.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,35000,0,0,2022-04-11T12:01:56-04:00
2771537,aafff3d0-cbb1-43af-a843-cd76d0987f0b,Q1,THE PRENDA GROUP LLC,401104543,UV-CONCEPTS,2022,first_quarter,MED,"Emergency response to COVID-19 Pandemic. Assistance to Hospitals / Veterans Administration Facilities / First Responders / Medical facilities etc. for patients, visitors, and healthcare workers. ULTRAVIOLET LIGHT ENCLOSURE TECHNOLOGY FOR BROAD APPLICATIONS IN HEALTHCARE AND NON-HEALTHCARE SECTORS. Monitoring COVID-19 Stimulus Packages and appropriations. Coronavirus Response and Relief","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-11T14:00:43-04:00
2771541,b0932b2f-9e3a-4b5a-ae24-f3aa2b8be4fe,Q1,THE PRENDA GROUP LLC,401104543,UV-CONCEPTS,2022,first_quarter,MED,"Emergency response to COVID-19 Pandemic. Assistance to Hospitals / Veterans Administration Facilities / First Responders / Medical facilities etc. for patients, visitors, and healthcare workers. ULTRAVIOLET LIGHT ENCLOSURE TECHNOLOGY FOR BROAD APPLICATIONS IN HEALTHCARE AND NON-HEALTHCARE SECTORS. Monitoring COVID-19 Stimulus Packages and appropriations. Coronavirus Response and Relief","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-11T14:01:02-04:00
2771690,d4bb5597-edcf-4786-8446-60bfe48f8e55,Q1,"THE CJR GROUP, INC.",288293,UNIVERSITY HOSPITALS HEALTH SYSTEM,2022,first_quarter,MED,Issues related to COVID-19 and funding for hospitals,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-04-11T19:19:52-04:00
2771947,5d537083-8aa4-4434-a4ca-ac63d655de20,Q1,MICHIGAN TECHNOLOGICAL UNIVERSITY,25181,MICHIGAN TECHNOLOGICAL UNIVERSITY,2022,first_quarter,MED,Discussed issues of interest related to higher education for the COVID-19 pandemic.,"HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2022-04-12T11:09:04-04:00
2772025,48621ffe-5dcb-4a0e-919c-0c27093dd355,Q1,CHAMBER HILL STRATEGIES,400645947,SANFORD HEALTH,2022,first_quarter,MED,"H.R. 6000, Cures 2.0 Act.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2022-04-12T11:53:05-04:00
2772319,88f3029e-991b-401b-bf08-5d9766b6a817,Q1,RELX INC.,49511,RELX INC,2022,first_quarter,MED,"Issues related to US-UK Cancer Summit and Cancer Moonshot initiative. Issues related to NIHs diversity, equity, inclusion and accessibility efforts.","Health & Human Services, Dept of (HHS)",,520000,0,0,2022-04-12T15:51:20-04:00
2772438,50484d2d-bcab-4921-8930-76ce1e21ba86,Q1,BOSE PUBLIC AFFAIRS GROUP,297294,AMERICAN ACADEMY OF ANESTHESIOLOGIST ASSISTANTS,2022,first_quarter,MED,issues related to licensure,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",10000,,0,0,2022-04-12T16:57:31-04:00
2772519,189df676-cbb9-4fd3-9b85-471860d8f9a4,Q1,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2022,first_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-04-12T18:39:48-04:00
2772621,b5eede66-8a3c-4d71-b0a3-ae58fb2a848b,Q1,"EFB ADVOCACY, LLC",401104430,UNITED FOR MEDICAL RESEARCH,2022,first_quarter,MED,Funding Issues Related to the National Institutes of Health,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-13T09:46:07-04:00
2772752,8b9fe306-d1d4-47a1-aba2-72a7d3cb4842,Q1,BEN BARNES GROUP LP,5415,HUNTSMAN CORPORATION,2022,first_quarter,MED,CMS Medicare,"HOUSE OF REPRESENTATIVES,SENATE",18750,,0,0,2022-04-13T11:07:06-04:00
2772760,ce469cf3-8885-455c-bef2-5c6416ba23c7,Q1,BEN BARNES GROUP LP,5415,ENVIGO RMS LLC,2022,first_quarter,MED,Medical/Disease Research,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2022-04-13T11:13:11-04:00
2772816,a7bf36d3-c158-4a0b-912b-28a6b499549c,Q1,IMPACT MANAGEMENT GROUP,401104137,ARKANSAS RESEARCH ALLIANCE,2022,first_quarter,MED,On behalf of client support continued and future funding for clinical research programs in Arkansas,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-13T11:54:45-04:00
2773008,83cc059c-dfb7-4073-83c3-28bdc0038e91,Q1,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),1466,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),2022,first_quarter,MED,"AACC joined with other healthcare groups in writing to the Senate HELP leadership endorsing S.3534, the Tracking Pathogens Act, which would support and enhance existing genomic sequencing and surveillance activities. AACC met with House and Senate staff urging that the Verifying Accurate Leading-edge IVCT Development (VALID) Act not be included in the Medical Device User Fee Amendments V legislative package that will be considered by Congress. AACC provided input to the Senate HELP committee on its draft ""Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act,"" which would rebuild and strengthen our nations public health infrastructure.","HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2022-04-13T14:50:02-04:00
2773101,56e4c60d-4020-49fa-b2b1-3bc3ee9a5ac5,Q1,AMERICAN ASSOCIATION FOR CANCER RESEARCH,400601833,AMERICAN ASSOCIATION FOR CANCER RESEARCH,2022,first_quarter,MED,Cancer research Oncology product review at the FDA Pediatric research and cancer care Clinical trials Diversity in clinical trials,"HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2022-04-13T15:57:46-04:00
2773370,c50088e4-72bc-4015-b3b2-2f381eff6512,Q1,"MCHUGH LEMAY ASSOC., LLC",401105253,CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO,2022,first_quarter,MED,Issues related to COVID testing - including the National Defense Authorization Act of 2023 (Not yet introduced).,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2022-04-13T18:34:11-04:00
2773422,d5e5a30c-ed87-4bdc-9920-f42818a8f2f9,Q1,NATURAL RESOURCE RESULTS LLC,321555,SHINE MEDICAL TECHNOLOGIES,2022,first_quarter,MED,Support funding at DOE for fusion technology development.,SENATE,30000,,0,0,2022-04-13T20:18:29-04:00
2773444,42498bda-5e65-4ac4-a665-baa5c85bbd36,Q1,BRAMER GROUP LLC,401103355,"TACTICAL MEDICAL SOLUTIONS, LLC",2022,first_quarter,MED,"Medical Training, FY 2022 NDAA","Army, Dept of (Other),Defense, Dept of (DOD)",8250,,0,0,2022-04-13T20:45:37-04:00
2773507,21a144d7-d22e-4ae9-8419-e0895dcbdc4c,Q1,"HELIX, INC.",401106164,"HELIX, INC.",2022,first_quarter,MED,"genomic research and testing, COVID-19 testing and research","Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,36520,0,0,2022-04-14T09:04:20-04:00
2773510,6f845dbf-cca2-4e9f-b1d2-f630c04f6272,Q1,DREXEL UNIVERSITY,40032273,DREXEL UNIVERSITY,2022,first_quarter,MED,"Research, education and other matters related to higher ed.","HOUSE OF REPRESENTATIVES,SENATE",,81000,0,0,2022-04-14T09:04:54-04:00
2773515,32cc3bd0-c464-4c51-8a4d-23f490dc7bb6,Q1,DREXEL UNIVERSITY,40032273,ST. CHRISTOPHER'S HOSPITAL FOR CHILDREN,2022,first_quarter,MED,Children's health and welfare,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-14T09:09:07-04:00
2773821,dc8372e7-e8b4-4002-946b-995e968f2dd1,Q1,60 PLUS ASSOCIATION,41988,60 PLUS ASSOCIATION,2022,first_quarter,MED,Support legislation that would revamp laboratory data reporting requirements under the Protecting Access to Medicare Act (PAMA).,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-14T12:13:30-04:00
2774250,e3fd2cc6-bb36-42b4-9ed8-a98fceb056cf,Q1,"FAMILIES USA FOUNDATION, INC.",14108,FAMILIES USA FOUNDATION INC,2022,first_quarter,MED,"S.1644Promising Pathway ActTo amend the Federal Food, Drug, and CosmeticActto establish a time-limited provisional approvalpathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.","HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2022-04-14T14:36:36-04:00
2774329,dcdfdce2-0e2d-4300-a85d-a9ab7c0c11cd,Q1,HACKENSACK MERIDIAN HEALTH,401104109,HACKENSACK MERIDIAN HEALTH,2022,first_quarter,MED,National Institutes of Health funding Biomedical research and the creation of ARPA-H Support for the Center for Discovery and Innovation,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,160000,0,0,2022-04-14T15:25:22-04:00
2774350,0842717a-c2e0-4289-8549-5c05d43cb39d,Q1,"DESIMONE CONSULTING, LLC",400931695,WE WORK FOR HEALTH,2022,first_quarter,MED,"Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; PDUFA Reauthorization; FY2022 Budget Reconciliation (H.R.5376).","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-14T15:36:00-04:00
2774415,f1d74385-df3a-4c26-837c-e0f8cad5522f,Q1,HAWLEY LLC,401105460,MLA ASSOCIATES ON BEHALF OF CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO,2022,first_quarter,MED,"Issues related to pathogen testing for COVID 19 and other diseases, including the not yet introduced National Defense Authorization Act for FY2023","Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-14T15:54:14-04:00
2774638,386312be-17a8-4aba-a832-d5e0a2f9d1cd,Q1,"GOVERNMENT COUNSEL, LLC",401105070,"HOOPER,LUNDY& BOOKMAN, PC (OBO ROCHE DIAGNOSTICS)",2022,first_quarter,MED,S.2209/H.R.4128-Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-04-14T18:31:12-04:00
2774781,4cd47678-deec-4373-8cc1-9c1c9fd25dd5,1T,FAEGRE DRINKER BIDDLE & REATH LLP,12631,DRUGS FOR NEGLECTED DISEASES INITIATIVE OF NORTH AMERICA,2022,first_quarter,MED,"Issues related to neglected diseases research and development, access, and drug pricing; COVID treatments research and development.",,,,0,1,2022-04-15T09:08:06-04:00
2774807,fcee4152-0716-4b1a-bb86-796730c86dfd,Q1,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2022,first_quarter,MED,"CHGME, NIH, PACT ACT, Genomics, Cures 2.0, ARP","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,34560,0,0,2022-04-15T09:18:52-04:00
2775052,31e5dda3-918d-4907-a4e2-1b552d07a9c1,Q1,STANFORD UNIVERSITY,36492,STANFORD UNIVERSITY,2022,first_quarter,MED,"H.R.708; S.168 Temporary Reciprocity to Ensure Access to Treatment Act H.R. 2256, S. 834 Resident Physician Shortage Reduction Act of 2021 Title VII HRSA Health Professions programs","HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2022-04-15T11:33:40-04:00
2775501,b68efb52-5a30-4d38-ad16-f15670459022,Q1,WASHINGTON UNIVERSITY IN ST. LOUIS,40031264,WASHINGTON UNIVERSITY IN ST LOUIS,2022,first_quarter,MED,General advocacy for NIH and other biomedical research. General advocacy supporting the continued responsible utilization of research animals. General support for the development of fair and effective organ transplant policies.,"HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2022-04-15T14:05:13-04:00
2775660,8689d831-c5bc-4eac-be70-b1f365692861,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,ADVANCED MEDICAL TECHNOLOGY ASSOCIATION,2022,first_quarter,MED,Congressional outreach related to health care issues.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-04-15T15:18:33-04:00
2775761,6b5c121f-a4ed-44be-a0c6-9981f9fe472a,Q1,"THE CORMAC GROUP, LLC",66773,KESSLER FOUNDATION,2022,first_quarter,MED,"Appropriations, DOD, TBI Research, Veterans Issues","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-15T16:12:40-04:00
2775784,4c87f995-b834-489f-a6be-3054f2010307,Q1,O'NEILL AND ASSOCIATES,73134,"POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN)",2022,first_quarter,MED,"healthcare, medical","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2022-04-15T16:19:38-04:00
2776001,45d560d5-0e70-4652-9624-4d6204098667,Q1,FORBES-TATE,400976792,AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION,2022,first_quarter,MED,Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-04-15T18:04:05-04:00
2776029,28cbeef6-57ba-434a-971a-9a881d6041bb,Q1,FORBES-TATE,400976792,"AMGEN USA, INC.",2022,first_quarter,MED,Issues related to Biosimilars.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-04-15T18:27:50-04:00
2776099,aa9540ac-048f-419f-b039-3ab692de7d8f,Q1,FORBES-TATE,400976792,CALIFORNIA LIFE SCIENCES ASSOCIATION,2022,first_quarter,MED,Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-15T20:01:24-04:00
2776129,59b8d1a2-6f93-4f4c-b8f7-e1ea200fcf69,Q1,FORBES-TATE,400976792,"COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION",2022,first_quarter,MED,Issues pertaining to government-wide federal regulation of cannabis.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-04-15T20:36:57-04:00
2776135,2768fb45-274e-46c1-9a96-1406b5161e2e,Q1,FORBES-TATE,400976792,CSL BEHRING,2022,first_quarter,MED,Issues related to COVID-19 response efforts.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-04-15T21:07:18-04:00
2776523,82c7a5ec-3aea-4ba9-926a-13df9491c5d9,Q1,FOLEY & LARDNER LLP,15042,CARDIAC RMS,2022,first_quarter,MED,Remote Cardiac Monitoring,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-16T14:13:48-04:00
2776538,485ba042-543a-4e6a-8d37-8f36c946b029,Q1,"K&L GATES, LLP",32098,"CHEMBIO DIAGNOSTICS, INC.",2022,first_quarter,MED,Issues related to disease diagnostics testing and manufacturing - no specific legislation.,"Health & Human Services, Dept of (HHS)",10000,,0,0,2022-04-16T14:22:05-04:00
2776598,e5f4d2b6-40a4-4874-9311-8e9b63462e39,Q1,CAPITOL COUNSEL LLC,313715,"BLUE EARTH DIAGNOSTICS, INC.",2022,first_quarter,MED,To gain support for adequate Medicare reimbursement for diagnostic radiopharmaceuticals; Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-16T15:31:30-04:00
2776626,7a01cb6c-473d-4283-9906-89f4108d14fa,Q1,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2022,first_quarter,MED,Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-04-16T16:01:12-04:00
2776663,8dbc3d08-93e6-476f-9df2-462ab90db6dd,Q1,CAPITOL COUNSEL LLC,313715,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2022,first_quarter,MED,Monitor health and tax legislation pertaining to the biotechnology industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-16T16:18:47-04:00
2776844,e193a3c7-cdf1-42a9-bfda-2cc0f62d9537,Q1,FOLEY & LARDNER LLP,15042,RHYTHM MANAGEMENT GROUP,2022,first_quarter,MED,Remote Cardiac Monitoring,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-16T22:11:15-04:00
2776861,8a94a480-2a11-432d-93b7-3c44ba68b1f8,Q1,FOLEY & LARDNER LLP,15042,VECTOR REMOTE CARE,2022,first_quarter,MED,Remote Cardiac Monitoring,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-16T22:37:05-04:00
2776967,a538f628-93d4-49e7-9496-79aed89551dc,Q1,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2022,first_quarter,MED,"Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This Program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities. Advocated for increased appropriations for HRSAs Integrated Substance Use Disorder Training Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. Advocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting underrepresented minority addiction medicine professionals, including SAMHSAs Minority Fellowship Program. Advocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and standards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings. Advocated for regulatory/sub-regulatory/application guidance that would require the use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant, including requiring each grantee delivering SUD treatment services to provide access to all FDA-approved medications for SUDs treated by that grantee. Advocated for a requirement that SAPT, State Opioid Response Grant (SOR), and Rural Communities Opioid Response Program grantees that receive grant funds for the delivery of addiction treatment services should be limited to Medicaid providers in order to better integrate federal grant dollars and Medicaid funds and Administration support for increased oversight and improved mechanisms for ensuring that such funding does not supplant the consistent and scalable funding that Medicaid (or Medicare) provides. Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so. Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers. Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who are incarcerated, during the 30-day period preceding their release from jail or prison. Advocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which would repeal the inmate exclusion that bars the use of federal Medicaid matching funds from covering health care services in jails and prisons. Advocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of 2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates. Advocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels. Advocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA. Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares continued ability, beyond the COVID-19 public health emergency, to reimburse for audio-only, SUD and mental health telehealth services after an in-person or telehealth evaluation. Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD. Advocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment. Advocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. Advocated for the Administration to increase promotion to State Medicaid programs of adoption of two, new sets of bundled G codes to increase or establish payment for outpatient opioid use disorder (OUD) treatment and treatment services provided by opioid treatment programs (OTPs) at Medicare payment rates or higher. Advocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment: Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating Kickbacks in Recovery Act Civil, as they may be applied to the implementation of contingency management (CM) for the treatment of addiction. Approval of a prescription to over the counter (OTC) switch for at least one naloxone product. This change would save lives and reduce existing barriers that prevent access to this critical medication; Regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet level of care standards set forth in The ASAM Criteria; Regulatory (or legislative) changes that would create a special registration exemption for jails, prisons, and their authorized personnel to prescribe and otherwise dispense controlled medications for initiation, maintenance or withdrawal management of OUD that is significantly less burdensome than currently applicable registration requirements in the Controlled Substances Act and related regulations. Such special registration should not limit the number of persons who are detained or incarcerated who can be treated with such medications by a qualified practitioner; Regulatory (or legislative) changes that would allow pharmacy dispensing and/or administration of methadone that has been prescribed by a legally authorized prescriber of controlled medications who is affiliated with an OTP or is a board-certified addiction specialist physician; Regulatory (or legislative) changes that would make permanent the opioid treatment program (OTP) flexibilities, including the methadone unsupervised dosing flexibilities, implemented during the COVID-19 Public Health Emergency while continuing study of the impact of these flexibilities; Assessment of current opioid order systems and monitoring programs to more fully understand the potential negative implications for patient access to buprenorphine at pharmacies and other controlled substance medications used to treat OUD; In the absence of Congressional action to eliminate the x-waiver, efforts to increase the DATA 2000 waiver patient limit -- aka, the applicable number; Issuance of regulations relating to a special registration for telemedicine, as was directed in Section 3232 of the SUPPORT Act of 2018. Advocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package. Advocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as ""time in treatment"" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers. Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs. Advocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. Supported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO). Supported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes. Joined advocacy efforts with Senate Committee on Finance, encouraging full extension of federal mental health and substance use disorder parity protections to Medicare, all of Medicaid, and TRICARE. Sent Congressional letter recommending closer coordination among relevant federal agencies, greater integration between primary care and behavioral health reimbursement, and robust funding for the addiction treatment workforce-- such as the Addiction Medicine Fellowship Program. ASAM also expressed support for legislation to ensure state compliance with mental health and addiction parity law and codification of audio-video telehealth prescribing flexibilities for the treatment of substance use disorder. Finally, ASAM called on federal legislators to consider new and promising strategies like contingency management Urged inclusion of the field of addiction medicine in reauthorizations of several SAMHSA programs as well as conveyed ways to improve clinician access to relevant addiction medicine education ASAM and ten other health professional associations have called for the FDA to immediately and fully retract its buprenorphine Drug Safety Communication of January 12, 2022. In their letter, the signatories maintain that the communication is based on flawed analysis. As part of the National Alliance for Underage Drinking, ASAM sent a letter to Representative Roybal-Allard, Representative Joyce, and Representative DeLauro in support of reauthorization of the Sober Truth on Preventing (STOP Act). First passed by Congress in 2006 and later reauthorized in the 21st Century Cures Act, the STOP Act aims to reduce underage age drinking through a comprehensive approach comprised of cost-effective, evidence-based strategies. On January 26th, ASAM submitted a comment letter to CMSs proposed rule Patient Protection and Affordable Care Act (ACA); HHS Notice of Benefit and Payment Parameters (the NBPP 2023 Rule). In its letter, ASAM supports, among other things: reinterpretation of the ACAs guaranteed availability requirement; the new interpretation would require issuers to enroll individuals with past-due premiums; reversion to pre-2020 non-discrimination protections that would prohibit certain exchanges, insurers, and agents and brokers from discriminating based on sexual orientation and gender identity; ensuring nondiscriminatory benefit design through refining the EHB nondiscrimination policy, providing a clear regulatory framework to evaluate plan benefit design and implementation based upon clinical guidelines and evidence; and requirements that issuers offer at least one standardized plan at every product network type, metal level, and in every service area where the issuer also offers non-standardized plans and that standardized plans use fixed copays instead of coinsurance. The letter also documents ASAMs general support for proposals related to network adequacy regulations, with recommendations for further refinement. On March 22, 2022, ASAM and other stakeholders sent a letter, spearheaded by former Representative Patrick J. Kennedy, to the Secretary of State Antony J. Blinken, and the U.S. Agency for International Development Administrator, Samantha Power. The letter urges mental health and substance use disorders (SUDs) be integrated in the U.S. - Ukraine relief efforts, and that the U.S. coordinate with multilateral health organizations and the World Health Organization to address mental health and SUDs caused and exacerbated by the invasion of Ukraine. ASAM joined a coalition letter to urge Congress to respond to a new and growing threat to our nations youth: e-cigarette manufacturers use of synthetic nicotine to evade Food and Drug Administration (FDA) oversight. Specifically, the letter urges Congress to quickly address this serious public health situation by enacting legislation at the earliest possible opportunity that enables FDAs Center for Tobacco Products to regulate synthetic nicotine products. ASAM joined a coalition letter to express support for the Food and Drug Administrations commitment to issuing proposed rules to prohibit menthol as a characterizing flavor in cigarettes and prohibit all characterizing flavors in cigars. Once issued, the letter urges FDA to move quickly to finalize and implement these life-saving rules. ASAM joined a coalition letter supporting the Into the Light for Maternal Mental Health and Substance Use Disorders Act of 2022, which would address critical issues of maternal mental health and well-being. ASAM joined a coalition letter urging Congress to support increased funding of important addiction prevention, treatment, harm reduction, and recovery support programs aimed at strengthening the addiction service workforce in Fiscal Year 2023. Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine. Supported HR 7246/S 3940 - the Student Athlete Opioid Misuse Prevention Act which would establish a grant program through SAMHSA to provide educational and training at the youth, high school, and collegiate level for students and student athletes themselves, as well as athletic directors, youth sports coaches and organizers, school administrators, and others on the signs and dangers of opioid and substance misuse, and strategies for prevention. Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare. Supported H.R.7116- the 9-8-8 Implementation Act which would provide resources needed to improve the nations mental health/substance use crisis system.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,90000,0,0,2022-04-17T10:29:17-04:00
2777194,83f2fad4-db8d-4a6c-990b-180b8856e8c7,Q1,CLARK STREET ASSOCIATES,401105692,QORVO,2022,first_quarter,MED,Issues related to COVID testing including National Defense Authorization Act for FY 2023 (not yet introduced).,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",180000,,0,0,2022-04-17T13:16:04-04:00
2777596,9bd7417b-a541-4c94-a2f1-f905ac53e70c,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2022,first_quarter,MED,"Representation on health-related issues including reimbursement, research, public-health & clinical care","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2022-04-17T21:49:00-04:00
2777623,b8b62dcc-9035-41c2-9e26-0c1460ff2544,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CITY OF HOPE MEDICAL CENTER,2022,first_quarter,MED,"Medicare/Medicaid reimbursement, clinical research","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-17T22:17:15-04:00
2777676,7f459b1d-24d6-44df-b2cc-f7b7819fbb89,Q1,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2022,first_quarter,MED,"Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-18T01:08:31-04:00
2777691,b654b8fe-adde-444d-a230-bb32d6579364,Q1,"MARSHALL & POPP, LLC",401105121,"BUTTERFLY NETWORK, INC.",2022,first_quarter,MED,"Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-04-18T06:45:44-04:00
2777724,6de2b5c2-a5b4-4f09-904a-08d98cc4d0c0,Q1,IMPACT MANAGEMENT GROUP,401104137,"CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE, INC.",2022,first_quarter,MED,Supporting the passage of H.R. 3173 - Improving Seniors' Timely Access to Care Act of 2021,HOUSE OF REPRESENTATIVES,,,0,0,2022-04-18T08:24:33-04:00
2777840,d34e649c-cab5-47d3-91ac-20acd2ca437d,Q1,MANATOS & MANATOS,23634,BARBARA ANN KARMANOS CANCER INSTITUTE,2022,first_quarter,MED,PPS-exemption,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-18T09:31:06-04:00
2778059,cdde247e-a5e2-4d1b-ada5-d875a321db65,Q1,TIBER CREEK GROUP,20744,JAZZ PHARMACEUTICALS,2022,first_quarter,MED,"Issues related to the FDA and S. 3032 - the FDA STATES Act (115th Congress), and Health and Human Services pertaining to CBD policies.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-04-18T10:42:43-04:00
2778458,bd7fe340-684b-48b2-b28a-6fb519e0fff4,Q1,AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS,52105,AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS,2022,first_quarter,MED,Support appropriations for the Peer-Reviewed Orthopaedic Research Program (PRORP). PRORP is a competitive grant program that funds research pertaining to extremity war injuries. Support Research through support of HR 869/S289 Research Investment to Spark the Economy (RISE) Act,"HOUSE OF REPRESENTATIVES,SENATE",,353803,0,0,2022-04-18T11:59:33-04:00
2778510,f317819a-7343-4d29-b261-db5cf36abf1f,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2022,first_quarter,MED,Support for robust funding for federal agencies that fund medical and disease research,"HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2022-04-18T12:08:43-04:00
2778572,1abcc167-866e-4a9b-bfed-69435f39765c,Q1,SQUIRE PATTON BOGGS,30906,ALLIANCE FOR BIOSECURITY,2022,first_quarter,MED,Preparedness and response as it relates to Biosecurity.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2022-04-18T12:20:11-04:00
2779051,5b8ed434-308a-456f-b6ea-8317485e0fba,Q1,"RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC)",400361684,PPLA,2022,first_quarter,MED,Pharmaceutical Labeling,Food & Drug Administration (FDA),18700,,0,0,2022-04-18T13:28:42-04:00
2779456,e8a0feb4-1146-42fc-b677-183629a0637c,Q1,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2022,first_quarter,MED,Increasing funding for Myotonic Dystrophy research. Fiscal Year 2023 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-18T14:42:28-04:00
2779469,c9c5a4b1-4356-4b9d-9d97-b0db24c1bce4,Q1,BLUEBIRD STRATEGIES,401105447,"MYRIAD GENETICS, INC.",2022,first_quarter,MED,Legislation to regulate clinical labs under CLIA and FDA.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-04-18T14:45:28-04:00
2779931,23c928ff-d008-4f9f-8b6f-ec09e308c9cd,Q1,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,GATEWAYS HOSPITAL & MENTAL HEALTH CENTER FOUNDATION,2022,first_quarter,MED,"FY 2022 Consolidated Appropriations Act, H.R. 2471, now P.L. 117-103 American Rescue Plan Act of 2021, H.R. 1319, now P.L. 117-2 Infrastructure Investment and Jobs Act, H.R. 3684, now P.L. 117-58 Build Back Better Act, H.R. 5376 CONNECT for Health Act, S. 1512, H.R. 2903 FY 2023 House, Senate Departments of Labor, Health & Human Services, and Education and Related Agencies Appropriations Bills FY 2023 House, Senate Department of Agriculture Appropriations Bills FY 2023 House, Senate Departments of Commerce and Justice, Science and Related Agencies Appropriations Bills FY 2023 House, Senate Financial Services and General Government Appropriations Bills FY 2023 House, Senate Department of Homeland Security Appropriations Bills FY 2023 House, Senate Departments of Transportation, Housing and Urban Development, and Related Agencies Appropriations Bills Pursuit of Grants with Federal Agencies House, Senate Comprehensive Addiction and Recovery Legislation House, Senate Legislation to Reform Behavioral Health and Substance Use Disorder Prevention and Treatment House, Senate Legislation to Fund FCC Broadband and Other Telehealth House, Senate Legislation to Train More Primary Care and Other Providers House Legislation to Implement Electronic Provider Consultations (E-Consults) with Related Telemedicine in Hospitals House, Senate Infrastructure Bills","Administration for Children & Families (ACF),Agency for Healthcare Research & Quality (AHRQ),Agriculture, Dept of (USDA),Bureau of Justice Assistance,Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Federal Communications Commission (FCC),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Justice, Dept of (DOJ),Office of Justice Program,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",15000,,0,0,2022-04-18T15:58:31-04:00
2779952,f0df2f30-12f8-498c-b54b-5e6057b2f874,Q1,"THE CONAFAY GROUP, LLC",401004840,ACADIA PHARMACEUTICALS INC.,2022,first_quarter,MED,Pharmaceutical research/Medicare and Medicaid Reform,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-18T16:01:08-04:00
2779997,b03b8a11-1496-4fe1-9dbf-888da067dee8,Q1,"THE CONAFAY GROUP, LLC",401004840,EMERGEX VACCINES HOLDING LTD.,2022,first_quarter,MED,"Infectious disease, influenza and respiratory disease research",,,,0,0,2022-04-18T16:11:02-04:00
2780117,e3b2f6a3-7e73-4dd4-a1ad-33f0d7e8d3e5,Q1,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,"CORNERSTONE CARE, INC.",2022,first_quarter,MED,"FY 2022 Consolidated Appropriations Act, H.R. 2471, now P.L. 117-103 American Rescue Plan Act of 2021, H.R. 1319, now P.L. 117-2 Infrastructure Investment and Jobs Act, H.R. 3684, now P.L. 117-58 Build Back Better Act, H.R. 537 CONNECT for Health Act, S. 1512, H.R. 2903 FY 2023 House, Senate Departments of Labor, Health & Human Services, and Education and Related Agencies Appropriations Bills FY 2023 House, Senate Department of Agriculture Appropriations Bills FY 2023 House, Senate Departments of Commerce and Justice, Science and Related Agencies Appropriations Bills FY 2023 House, Senate Financial Services and General Government Appropriations Bills FY 2023 House, Senate Department of Homeland Security Appropriations Bills Pursuit of Grants with Federal Agencies House, Senate Comprehensive Addiction and Recovery Legislation House, Senate Legislation to Reform Behavioral Health and Substance Use Disorder Prevention and Treatment House, Senate Legislation to Fund FCC Broadband and Other Telehealth House, Senate Legislation to Train More Primary Care and Other Providers House Legislation to Implement Electronic Provider Consultations (E-Consults) with Related Telemedicine in Hospitals and Health Centers House, Senate Infrastructure Bills","Appalachian Regional Commission,Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Economic Development Administration,Federal Communications Commission (FCC),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Treasury, Dept of",,,0,0,2022-04-18T16:28:48-04:00
2780128,47e2d871-7845-43da-b7c0-a08d3b4571f4,Q1,BRACEWELL LLP,6837,AIR LIQUIDE USA LLC,2022,first_quarter,MED,work related to medical gases,"HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2022-04-18T16:30:45-04:00
2780159,bd38f645-202a-4cf8-bf8f-006da81cea3e,Q1,"THE CONAFAY GROUP, LLC",401004840,SECURING AMERICAS MEDICINES AND SUPPLY SAMS,2022,first_quarter,MED,Strengthening the medical supply chain,"Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-18T16:34:44-04:00
2780162,b4bc9956-50a8-457e-b4f4-cb96882f09e1,Q1,IMPACT HEALTH POLICY PARTNERS,401104696,ABBOTT LABORATORIES,2022,first_quarter,MED,"Issues related to coverage and reimbursement for durable medical equipment, medical devices, diagnostics and nutrition.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-18T16:34:51-04:00
2780176,26f8da0c-b018-422c-9246-77c243ab2924,Q1,IMPACT HEALTH POLICY PARTNERS,401104696,CHILDREN'S HOSPITAL COLORADO,2022,first_quarter,MED,"Issues related to pediatric research and children's hospital graduate medical education. H.R.6000, Cures 2.0 Act.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-18T16:36:14-04:00
2780254,4a9c1e29-72c6-48d6-9ae0-f89ff5c54cc3,Q1,IMPACT HEALTH POLICY PARTNERS,401104696,HACKENSACK MERIDIAN HEALTH,2022,first_quarter,MED,"Issues related to research funding, including ARPA-H, NIH, organ transplants, and other matters. H.R.6000, Cures 2.0 Act.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",40000,,0,0,2022-04-18T16:40:48-04:00
2780274,0f8a70e6-1748-4516-b956-312746d47efd,Q1,"THE CONAFAY GROUP, LLC",401004840,THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT),2022,first_quarter,MED,Support for trauma research,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-04-18T16:43:49-04:00
2780364,307c0566-055b-4768-888a-3b44c94a4bf5,Q1,"THE CONAFAY GROUP, LLC",401004840,ANI PHARMACEUTICALS,2022,first_quarter,MED,Support for medical research,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-18T16:55:17-04:00
2780481,053405a2-0ece-40ce-bb93-668d3486caaa,Q1,"THE CONAFAY GROUP, LLC",401004840,"CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.)",2022,first_quarter,MED,Federal support to advance medical research,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-18T17:18:35-04:00
2780627,84cb4a1f-57e7-4ca3-84b1-94d60cb644d8,Q1,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,PIH HEALTH FOUNDATION,2022,first_quarter,MED,"FY 2022 Consolidated Appropriations Act, H.R. 2471, now P.L. 117-103 American Rescue Plan Act of 2021, H.R. 1319, now P.L. 117-2 Infrastructure Investment and Jobs Act, H.R. 3684, now P.L. 117-58 Build Back Better Act, H.R. 5376 CONNECT for Health Act, S. 1512, H.R. 2903 FY 2023 House, Senate Departments of Labor, Health & Human Services, and Education and Related Agencies Appropriations Bills FY 2023 House, Senate Department of Agriculture Appropriations Bills FY 2023 House, Senate Departments of Commerce and Justice, Science and Related Agencies Appropriations Bills FY 2023 House, Senate Financial Services and General Government Appropriations Bills FY 2023 House, Senate Department of Homeland Security Appropriations Bills Pursuit of Grants with Federal Agencies House, Senate Legislation to Fund FCC Broadband and Other Telehealth House, Senate Legislation to Train More Primary Care and Other Providers House Legislation to Implement Electronic Provider Consultations (E-Consults) with Related Telemedicine in Hospitals House, Senate Infrastructure Bills","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Federal Communications Commission (FCC),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",30000,,0,0,2022-04-18T18:02:04-04:00
2780907,57b372bb-4c91-41ac-8b37-6823956f7c7d,Q1,THE RABEN GROUP,61458,EXAGEN INC,2022,first_quarter,MED,Educate House and Senate members on the uses of a Lupus early diagnosis test,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-04-18T20:26:00-04:00
2780997,e2fd2423-ab42-40d5-bdc6-9078e20244d9,Q1,"BLUESTONE STRATEGIES, LLC",400658980,VALYRIAN SMOKE LLC,2022,first_quarter,MED,Medical Research and Funding for Traumatic Brain Injury and Post-Traumatic Stress Disorder,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-04-18T21:14:10-04:00